Asher Biotherapeutics, Inc. announced that it will receive $54,999,990 in funding on April 3, 2024. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,062 GBX | +0.32% | +7.22% | +13.79% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,062 GBX | +0.32% | +7.22% | 234B | ||
43.94 USD | -1.57% | -10.31% | 90.49B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.79% | 234B | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B | |
-11.01% | 145B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Asher Biotherapeutics, Inc. announced that it expects to receive $54.99999 million in funding